Jonathan W. Lo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jonathan W. Lo has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Graham M. Lord
School of Immunology and Microbial Sciences, King’s College London, London, United Kingdom
6 shared publications - Tamas Korcsmaros
Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London
5 shared publications Luke B. Roberts
School of Immunology and Microbial Sciences, King’s College London, London, UK
4 shared publicationsMatthew Madgwick
Division of Digestive Diseases, Faculty of Medicine, Imperial College London, London, UK
4 shared publicationsNick Powell
Imperial College London
4 shared publications- Richard G. Jenner
UCL Cancer Institute and CRUK City of London Centre, University College London, London, UK
4 shared publications
Latest Publications
- Open Access
- 4 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
CTLA-4 expressing innate lymphoid cells modulate mucosal homeostasis in a microbiota dependent manner
The maintenance of intestinal homeostasis is a fundamental process critical for organismal integrity. Sitting at the interface of the gut microbiome and mucosal immunity, adaptive and innate lymphoid populations regulate the balance between commensal micro-organisms and pathogens. Checkpoint inhibitors, particularly those targeting the CTLA-4 pathway, disrupt this fine balance and can lead to inflammatory bowel disease and immune checkpoint colitis. Here, we show that CTLA-4 is expressed by innate lymphoid cells and that its expression is regulated by ILC subset-specific cytokine cues in a microbiota-dependent manner. Genetic deletion or antibody blockade of CTLA-4 in multiple in vivo models of colitis demonstrates that this pathway plays a key role in intestinal homeostasis. Lastly, we have found that this observation is conserved in human IBD. We propose that this population of CTLA-4-positive ILC may serve as an important target for the treatment of idiopathic and iatrogenic intestinal inflammation.
- 4 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Open AccessCTLA-4 expressing innate lymphoid cells modulate mucosal homeostasis in a microbiota dependent manner
The maintenance of intestinal homeostasis is a fundamental process critical for organismal integrity. Sitting at the interface of the gut microbiome and mucosal immunity, adaptive and innate lymphoid populations regulate the balance between commensal micro-organisms and pathogens. Checkpoint inhibitors, particularly those targeting the CTLA-4 pathway, disrupt this fine balance and can lead to inflammatory bowel disease and immune checkpoint colitis. Here, we show that CTLA-4 is expressed by innate lymphoid cells and that its expression is regulated by ILC subset-specific cytokine cues in a microbiota-dependent manner. Genetic deletion or antibody blockade of CTLA-4 in multiple in vivo models of colitis demonstrates that this pathway plays a key role in intestinal homeostasis. Lastly, we have found that this observation is conserved in human IBD. We propose that this population of CTLA-4-positive ILC may serve as an important target for the treatment of idiopathic and iatrogenic intestinal inflammation.
- Open Access
- 23 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-20
Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23/IFNγ axis
Immune checkpoint inhibitors (CPIs) are a relatively newly licenced cancer treatment, which make a once previously untreatable disease now amenable to a potential cure. Combination regimens of anti-CTLA4 and anti-PD-1 show enhanced efficacy but are prone to off-target immune-mediated tissue injury, particularly at the barrier surfaces. To probe the impact of immune checkpoints on intestinal homoeostasis, mice are challenged with anti-CTLA4 and anti-PD-1 immunotherapy and manipulation of the intestinal microbiota. The immune profile of the colon of these mice with CPI-colitis is analysed using bulk RNA sequencing, single-cell RNA sequencing and flow cytometry. CPI-colitis in mice is dependent on the composition of the intestinal microbiota and by the induction of lymphocytes expressing interferon-γ (IFNγ), cytotoxicity molecules and other pro-inflammatory cytokines/chemokines. This pre-clinical model of CPI-colitis could be attenuated following blockade of the IL23/IFNγ axis. Therapeutic targeting of IFNγ-producing lymphocytes or regulatory networks, may hold the key to reversing CPI-colitis.
- 23 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-20
Open AccessImmune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23/IFNγ axis
Immune checkpoint inhibitors (CPIs) are a relatively newly licenced cancer treatment, which make a once previously untreatable disease now amenable to a potential cure. Combination regimens of anti-CTLA4 and anti-PD-1 show enhanced efficacy but are prone to off-target immune-mediated tissue injury, particularly at the barrier surfaces. To probe the impact of immune checkpoints on intestinal homoeostasis, mice are challenged with anti-CTLA4 and anti-PD-1 immunotherapy and manipulation of the intestinal microbiota. The immune profile of the colon of these mice with CPI-colitis is analysed using bulk RNA sequencing, single-cell RNA sequencing and flow cytometry. CPI-colitis in mice is dependent on the composition of the intestinal microbiota and by the induction of lymphocytes expressing interferon-γ (IFNγ), cytotoxicity molecules and other pro-inflammatory cytokines/chemokines. This pre-clinical model of CPI-colitis could be attenuated following blockade of the IL23/IFNγ axis. Therapeutic targeting of IFNγ-producing lymphocytes or regulatory networks, may hold the key to reversing CPI-colitis.
- Open Access
- 27 March 2023
- Published by Springer Nature in Research Square
Microbiota-dependent expression of CTLA-4 by innate lymphoid cells restrains IFNγ dependent colitis
The maintenance of intestinal homeostasis is a fundamental process critical for organismal integrity. Sitting at the interface of the gut microbiome and mucosal immunity, adaptive and innate lymphoid populations regulate the balance between commensal micro-organisms and pathogens. Checkpoint inhibitors (CPI), particularly those targeting the CTLA-4 pathway, disrupt this fine balance and can lead to inflammatory bowel disease (IBD) and immune checkpoint colitis (CPI-C). Here, we show that CTLA-4 is expressed by innate lymphoid cells (ILC) and that its expression is regulated by ILC subset-specific cytokine cues in a microbiota-dependent manner. Genetic deletion or antibody blockade of CTLA-4 demonstrates that this pathway plays a key role in intestinal homeostasis and is conserved in human IBD and CPI-induced colitis (CPI-C). We propose that this population of CTLA-4-positive ILC may serve as an important target for the treatment of idiopathic and iatrogenic intestinal inflammation.
- 27 March 2023
- Published by Springer Nature in Research Square
Open AccessMicrobiota-dependent expression of CTLA-4 by innate lymphoid cells restrains IFNγ dependent colitis
The maintenance of intestinal homeostasis is a fundamental process critical for organismal integrity. Sitting at the interface of the gut microbiome and mucosal immunity, adaptive and innate lymphoid populations regulate the balance between commensal micro-organisms and pathogens. Checkpoint inhibitors (CPI), particularly those targeting the CTLA-4 pathway, disrupt this fine balance and can lead to inflammatory bowel disease (IBD) and immune checkpoint colitis (CPI-C). Here, we show that CTLA-4 is expressed by innate lymphoid cells (ILC) and that its expression is regulated by ILC subset-specific cytokine cues in a microbiota-dependent manner. Genetic deletion or antibody blockade of CTLA-4 demonstrates that this pathway plays a key role in intestinal homeostasis and is conserved in human IBD and CPI-induced colitis (CPI-C). We propose that this population of CTLA-4-positive ILC may serve as an important target for the treatment of idiopathic and iatrogenic intestinal inflammation.
O32 The interleukin 22//neutrophil axis is associated with treatment resistance in ulcerative colitis
Introduction Interleukin (IL) 22 is a key cytokine involved in regulation of epithelial function and its role in IBD remains highly controversial. Some studies indicate a protective role in epithelial regeneration, whereas other studies imply a pro-inflammatory role. Insights are now needed to improve of understanding of the functional role of this important cytokine and how its expression might impact patients with ulcerative colitis (UC). In this study, we have probed the clinical and functional significance of IL-22 responsive transcriptional modules and causal networks in diseased tissue of over 500 UC patients and in preclinical models of colitis. Methods We mapped the transcriptional landscape of human colonic epithelial 3D mini-gut organoids in response to treatment with IL22, and other pro-inflammatory cytokines. We tested the clinical significance of the IL22-regulated transcriptome by probing whole colonic biopsies from 550 ulcerative colitis (UC) patients from UNIFI clinical trial programme (patients with UC treated with ustekinumab, an anti-IL12p40 antibody). The functional role of IL22 regulated biological pathways were evaluated in pre-clinical models of UC. Results IL-22 regulated pro-inflammatory biological pathways involved in microbial recognition, cancer and immune cell chemotaxis. IL-22 was an especially potent regulator of the CXC family chemokines CXCL1, CXCL2, CXCL5, CXCL6 and CXCL8, which are all powerful neutrophil-selective chemokines. There was a positive correlation between the IL-22 transcriptional programme and the histological severity of inflammation (r=0.49, p+ neutrophils to the colon. Conclusions The interleukin 22/neutrophil axis is functionally important in colitis and is associated with treatment resistance in ulcerative colitis
O32 The interleukin 22//neutrophil axis is associated with treatment resistance in ulcerative colitis
Introduction Interleukin (IL) 22 is a key cytokine involved in regulation of epithelial function and its role in IBD remains highly controversial. Some studies indicate a protective role in epithelial regeneration, whereas other studies imply a pro-inflammatory role. Insights are now needed to improve of understanding of the functional role of this important cytokine and how its expression might impact patients with ulcerative colitis (UC). In this study, we have probed the clinical and functional significance of IL-22 responsive transcriptional modules and causal networks in diseased tissue of over 500 UC patients and in preclinical models of colitis. Methods We mapped the transcriptional landscape of human colonic epithelial 3D mini-gut organoids in response to treatment with IL22, and other pro-inflammatory cytokines. We tested the clinical significance of the IL22-regulated transcriptome by probing whole colonic biopsies from 550 ulcerative colitis (UC) patients from UNIFI clinical trial programme (patients with UC treated with ustekinumab, an anti-IL12p40 antibody). The functional role of IL22 regulated biological pathways were evaluated in pre-clinical models of UC. Results IL-22 regulated pro-inflammatory biological pathways involved in microbial recognition, cancer and immune cell chemotaxis. IL-22 was an especially potent regulator of the CXC family chemokines CXCL1, CXCL2, CXCL5, CXCL6 and CXCL8, which are all powerful neutrophil-selective chemokines. There was a positive correlation between the IL-22 transcriptional programme and the histological severity of inflammation (r=0.49, p+ neutrophils to the colon. Conclusions The interleukin 22/neutrophil axis is functionally important in colitis and is associated with treatment resistance in ulcerative colitis
- Open Access
- 12 February 2022
- Published by Wiley in European Journal of Immunology
- Vol. 52 (4) , 566-581
A population of naive‐like CD4+ T cells stably polarized to the TH1 lineage
T‐bet is the lineage‐specifying transcription factor for CD4+ TH1 cells. T‐bet has also been found in other CD4+ T cell subsets, including TH17 cells and Treg, where it modulates their functional characteristics. However, we lack information on when and where T‐bet is expressed during T cell differentiation and how this impacts T cell differentiation and function. To address this, we traced the ontogeny of T‐bet‐expressing cells using a fluorescent fate‐mapping mouse line. We demonstrate that T‐bet is expressed in a subset of CD4+ T cells that have naïve cell surface markers and transcriptional profile and that this novel cell population is phenotypically and functionally distinct from previously described populations of naïve and memory CD4+ T cells. Naïve‐like T‐bet‐experienced cells are polarized to the TH1 lineage, predisposed to produce IFN‐γ upon cell activation, and resist repolarization to other lineages in vitro and in vivo. These results demonstrate that lineage‐specifying factors can polarize T cells in the absence of canonical markers of T cell activation and that this has an impact on the subsequent T‐helper response.
- 12 February 2022
- Published by Wiley in European Journal of Immunology
- Vol. 52 (4) , 566-581
Open AccessA population of naive‐like CD4+ T cells stably polarized to the TH1 lineage
T‐bet is the lineage‐specifying transcription factor for CD4+ TH1 cells. T‐bet has also been found in other CD4+ T cell subsets, including TH17 cells and Treg, where it modulates their functional characteristics. However, we lack information on when and where T‐bet is expressed during T cell differentiation and how this impacts T cell differentiation and function. To address this, we traced the ontogeny of T‐bet‐expressing cells using a fluorescent fate‐mapping mouse line. We demonstrate that T‐bet is expressed in a subset of CD4+ T cells that have naïve cell surface markers and transcriptional profile and that this novel cell population is phenotypically and functionally distinct from previously described populations of naïve and memory CD4+ T cells. Naïve‐like T‐bet‐experienced cells are polarized to the TH1 lineage, predisposed to produce IFN‐γ upon cell activation, and resist repolarization to other lineages in vitro and in vivo. These results demonstrate that lineage‐specifying factors can polarize T cells in the absence of canonical markers of T cell activation and that this has an impact on the subsequent T‐helper response.
- Open Access
- 20 January 2022
- Published by Springer Nature in Research Square
Immune checkpoint inhibitor-induced colitis is mediated by CXCR6+ polyfunctional lymphocytes and is dependent on the IL23/IFNγ axis
Immune checkpoint inhibitors (CPIs) have revolutionised cancer treatment, with previously untreatable disease now amenable to potential cure. Combination regimens of anti-CTLA-4 and anti-PD-1 show enhanced efficacy but are prone to off-target immune-mediated tissue injury, particularly at the barrier surfaces. CPI-induced colitis is a common and serious complication. To probe the impact of immune checkpoints on intestinal homeostasis, mice were challenged with combination anti-CTLA-4/anti-PD-1 immunotherapy and manipulation of the intestinal microbiota. Colonic immune responses were profiled using bulk and single-cell RNA-sequencing and flow cytometry. CPI-colitis was dependent on the composition of the intestinal microbiota and was characterized by remodelling of mucosal lymphocytes with induction of polyfunctional lymphocyte responses characterized by increased expression of interferon-γ (IFNγ), other pro-inflammatory cytokines/chemokines (Il22, Il17a Ccl3, Ccl4 and Ccl9), cytotoxicity molecules (Gzmb, Gzma, Prf1, Nkg7) and the chemokine receptor Cxcr6. In comparison with mucosal lymphocytes in the steady state, polyfunctional lymphocytes from both CD4+ and CD8+ lineages upregulated costimulatory molecules and checkpoint molecules in CPI-colitis, indicating that these cells are tightly regulated. CPI-colitis was attenuated following depletion of effector lymphocytes or following blockade of the IL23/IFNγ axis. This study provides new mechanistic insights into CPI-colitis, identifying polyfunctional, cytotoxic lymphocytes as key mediators of disease. Therapeutic targeting of their effector response or regulatory networks, including the IL23/IFNγ axis likely holds the key to preventing and reversing CPI-colitis.
- 20 January 2022
- Published by Springer Nature in Research Square
Open AccessImmune checkpoint inhibitor-induced colitis is mediated by CXCR6+ polyfunctional lymphocytes and is dependent on the IL23/IFNγ axis
Immune checkpoint inhibitors (CPIs) have revolutionised cancer treatment, with previously untreatable disease now amenable to potential cure. Combination regimens of anti-CTLA-4 and anti-PD-1 show enhanced efficacy but are prone to off-target immune-mediated tissue injury, particularly at the barrier surfaces. CPI-induced colitis is a common and serious complication. To probe the impact of immune checkpoints on intestinal homeostasis, mice were challenged with combination anti-CTLA-4/anti-PD-1 immunotherapy and manipulation of the intestinal microbiota. Colonic immune responses were profiled using bulk and single-cell RNA-sequencing and flow cytometry. CPI-colitis was dependent on the composition of the intestinal microbiota and was characterized by remodelling of mucosal lymphocytes with induction of polyfunctional lymphocyte responses characterized by increased expression of interferon-γ (IFNγ), other pro-inflammatory cytokines/chemokines (Il22, Il17a Ccl3, Ccl4 and Ccl9), cytotoxicity molecules (Gzmb, Gzma, Prf1, Nkg7) and the chemokine receptor Cxcr6. In comparison with mucosal lymphocytes in the steady state, polyfunctional lymphocytes from both CD4+ and CD8+ lineages upregulated costimulatory molecules and checkpoint molecules in CPI-colitis, indicating that these cells are tightly regulated. CPI-colitis was attenuated following depletion of effector lymphocytes or following blockade of the IL23/IFNγ axis. This study provides new mechanistic insights into CPI-colitis, identifying polyfunctional, cytotoxic lymphocytes as key mediators of disease. Therapeutic targeting of their effector response or regulatory networks, including the IL23/IFNγ axis likely holds the key to preventing and reversing CPI-colitis.
- Open Access
A population of CD4 + T cells with a naïve phenotype stably polarized to the T H 1 lineage
T-bet is the lineage-specifying transcription factor for CD4 + T helper type 1 (T H 1) cells. T-bet has also been found in other CD4 + T cell subsets, including T H 17 cells and T REG , where it modulates their functional characteristics. However, we lack information on when and where T-bet is expressed during T cell differentiation and how this impacts T cell function. To address this, we traced the ontogeny of T-bet-expressing cells using a fluorescent fate-mapping mouse line. We demonstrate that T-bet is expressed in a subset of CD4 + T cells with naïve cell surface markers and that this novel cell population is phenotypically and functionally distinct from conventional naïve CD4 + T cells. These cells are also distinct from previously described populations of memory phenotype and stem cell-like T cells. Naïve-like T-bet-experienced cells are polarised to the T H 1 lineage, predisposed to produce IFNγ upon cell activation, and resist repolarisation to other lineages in vitro and in vivo . These results demonstrate that lineage-specifying factors can function to polarise T cells in the absence of canonical markers of T cell activation and that this has an impact on the subsequent T helper response.
Open AccessA population of CD4 + T cells with a naïve phenotype stably polarized to the T H 1 lineage
T-bet is the lineage-specifying transcription factor for CD4 + T helper type 1 (T H 1) cells. T-bet has also been found in other CD4 + T cell subsets, including T H 17 cells and T REG , where it modulates their functional characteristics. However, we lack information on when and where T-bet is expressed during T cell differentiation and how this impacts T cell function. To address this, we traced the ontogeny of T-bet-expressing cells using a fluorescent fate-mapping mouse line. We demonstrate that T-bet is expressed in a subset of CD4 + T cells with naïve cell surface markers and that this novel cell population is phenotypically and functionally distinct from conventional naïve CD4 + T cells. These cells are also distinct from previously described populations of memory phenotype and stem cell-like T cells. Naïve-like T-bet-experienced cells are polarised to the T H 1 lineage, predisposed to produce IFNγ upon cell activation, and resist repolarisation to other lineages in vitro and in vivo . These results demonstrate that lineage-specifying factors can function to polarise T cells in the absence of canonical markers of T cell activation and that this has an impact on the subsequent T helper response.
- Open Access
- 1 January 2020
- Published by Elsevier in SSRN Electronic Journal
Checkpoint Inhibitor Induced Colitis is Dependent on the Microbiota and Activation of Cytotoxic Innate and Adaptive Lymphocytes
Immune checkpoint inhibitors (CPI) have revolutionised cancer treatment, with previously untreatable disease now amenable to potential cure. Combination regimens of anti-CTLA4 and anti-PD-1 show enhanced efficacy but are prone to off target immune-mediated tissue injury, particularly at the barrier surfaces. We show that CPI-induced colitis is dependent on the composition of the intestinal microbiota and involves innate immune mechanisms. Single cell RNA sequencing identified remodelling of mucosal lymphocytes in CPI-induced colitis, including the emergence of polyfunctional, cytolytic responses in CD4+ T-cells and innate lymphoid cells (ILCs). Unexpectedly, colitis deteriorated following CD4+ T-cell depletion and was maintained in mice lacking adaptive immunity. We show that both human and mouse colonic ILCs express CTLA4, which is regulated by microbial and inflammatory cues, and is functionally important in restraining innate immune activation. We provide new mechanistic insights into immune regulation at the mucosal barrier and important implications for the treatment of CPI-induced autoimmunity.
- 1 January 2020
- Published by Elsevier in SSRN Electronic Journal
Open AccessCheckpoint Inhibitor Induced Colitis is Dependent on the Microbiota and Activation of Cytotoxic Innate and Adaptive Lymphocytes
Immune checkpoint inhibitors (CPI) have revolutionised cancer treatment, with previously untreatable disease now amenable to potential cure. Combination regimens of anti-CTLA4 and anti-PD-1 show enhanced efficacy but are prone to off target immune-mediated tissue injury, particularly at the barrier surfaces. We show that CPI-induced colitis is dependent on the composition of the intestinal microbiota and involves innate immune mechanisms. Single cell RNA sequencing identified remodelling of mucosal lymphocytes in CPI-induced colitis, including the emergence of polyfunctional, cytolytic responses in CD4+ T-cells and innate lymphoid cells (ILCs). Unexpectedly, colitis deteriorated following CD4+ T-cell depletion and was maintained in mice lacking adaptive immunity. We show that both human and mouse colonic ILCs express CTLA4, which is regulated by microbial and inflammatory cues, and is functionally important in restraining innate immune activation. We provide new mechanistic insights into immune regulation at the mucosal barrier and important implications for the treatment of CPI-induced autoimmunity.